Coccidioidomycosis (Valley Fever): When to Stop Antifungal Treatment
1. The most sensitive biomarkers for diagnosing coccidioidomycosis (Valley Fever, VF) is antibody testing — a quantitative canine IgG antibody EIA combined with antibody immunodiffusion (ID) — with combined sensitivity exceeding 98% in dogs
2. Coccidioides antigen testing is less sensitive at diagnosis than antibody testing, but when positive, antigen testing should be negative before stopping treatment
3. Antibody ID is the single best test for treatment monitoring. IgM (TP) should be negative, and IgG (CF) should be negative, or low positive, before stopping treatment (Table 1).
4. Treatment monitoring is multimodal and should combine clinical signs, physical exam findings, imaging studies, and antigen/antibody testing — no single tool should be used in isolation.
Background:
Valley Fever is caused by Coccidioides immitis and C. posadasii and is endemic to the semiarid southwestern U.S., though its geographic range appears to be expanding with warmer, drier conditions. Infection follows inhalation of arthroconidia aerosolized from disturbed soil. Dogs are diagnosed with VF significantly more often than cats. Pulmonary disease (lung and associated lymph nodes) is the most common presentation in dogs, while disseminated disease predominates in cats.
Diagnostic Testing
Diagnosis is supported by finding organisms (spherules and endospores) in cytology or histopathology and by serologic testing. The most sensitive diagnostic approach combines two antibody tests — a quantitative canine IgG antibody enzyme immunoassay (EIA) and antibody immunodiffusion (ID), which detects tube precipitin (TP/IgM) and complement fixation (CF/ IgG) antibodies. Only a minority of dogs (roughly 20-45%) are TP (IgM) positive at diagnosis, so a negative IgM result alone does not rule out infection; the combined use of IgG EIA and ID improves overall sensitivity to greater than 98% in dogs.
A galactomannan antigen test is also available but has lower diagnostic sensitivity than antibody testing at the time of diagnosis, likely because Coccidioides sheds little antigen compared with other dimorphic fungi. Antigen testing is most useful in seronegative cases and becomes one of the tools for monitoring once an animal has a positive result.
An important interpretive caveat applies to antibody titers; CF (IgG) titers up to 1:16 have been reported in clinically healthy dogs residing in endemic regions, reflecting prior exposure rather than active disease. Antibody results — whether by EIA or ID — should therefore always be interpreted alongside clinical signs, physical exam findings, and imaging, and followed as a trend over time rather than used as a stand-alone diagnostic or monitoring criterion.
Treatment Duration and Monitoring
Most dogs with pulmonary VF often achieve clinical remission within 6-9 months of antifungal therapy (typically fluconazole) and can have treatment discontinued at that point if monitoring criteria are met (Table 1). Disseminated disease — more common in cats and in dogs with bone/joint, CNS, or other extrapulmonary involvement — generally requires longer treatment (12 months or more); and CNS disease often warrants indefinite azole therapy. Relapse after treatment discontinuation, has been reported in roughly 15% of dogs with pulmonary VF and roughly 35% of cats with disseminated VF, underscoring the value of a multimodal monitoring approach (Table 1) rather than reliance on a fixed treatment duration alone.
| Monitoring Tool | Criteria | Notes |
|---|---|---|
| Treatment Duration | Minimum of 6 months (pulmonary disease) or 12 months (disseminated disease) | Required duration is frequently longer, particularly for disseminated disease. CNS involvement often warrants indefinite fluconazole therapy. |
| History | Past resolution of clinical signs | Mild exercise intolerance may persist, most notable in working or performance dogs. |
| Physical Examination | Past resolution of physical exam abnormalities | Differentiate active ocular disease from permanent, inactive change. |
| Imaging Studies | Past resolution of imaging abnormalities | Enlarged tracheobronchial lymph nodes decrease most significantly in the first 3 months of treatment. Radiographic bone lesions should improve but may never fully normalize. |
| Coccidioides Antigen (if positive at diagnosis) | Negative | Serum is the sample type used for the quantitative antigen EIA. Submit at diagnosis and every 3 months during treatment. |
| Coccidioides Antibody ID | Antibody ID: CF (IgG) titer ≤1:4, OR ≤1:8 after ≥1 year of treatment | Submit at diagnosis and every 3 months during treatment. |
| 1-month | History / PE Biochemistry Itra blood level |
| 3-months | History / PE Biochemistry Antibody ID + / – Antigen Imaging |
| 6-months | History / PE Biochemistry Antibody ID + / – Antigen Imaging Itra blood level |
| 9-months | History / PE Biochemistry Antibody ID + / – Antigen Imaging |
| 12-months | History / PE Biochemistry Antibody ID + / – Antigen Imaging Itra blood level |
References
- Holbrook ED, Greene RT, Rubin SI, et al. Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs. Med Mycol. 2019;57(7):800-806.
- Kirsch EJ, Greene RT, Prahl A, et al. Evaluation of Coccidioides antigen detection in dogs with coccidioidomycosis. Clin Vaccine Immunol. 2012;19(3):343-345.
- Johnson LR, Herrgesell EJ, Davidson AP, Pappagianis D. Clinical, clinicopathologic, and radiographic findings in dogs with coccidioidomycosis: 24 cases (1995-2000). J Am Vet Med Assoc. 2003;222(4):461-466.
- Gunstra A, Steurer JA, Seibert RL, et al. Sensitivity of serologic testing for dogs diagnosed with coccidioidomycosis on histology: 52 cases (2012-2013). J Am Anim Hosp Assoc. 2019;55(5):238-242.
- Chow NA, Lindsley MD, McCotter OZ, et al. Development of an enzyme immunoassay for detection of antibodies against Coccidioides in dogs and other mammalian species. PLoS One. 2017;12(4):e0175081.
- Shubitz LE, Butkiewicz CD, Dial SM, et al. Incidence of coccidioides infection among dogs residing in a region in which the organism is endemic. J Am Vet Med Assoc. 2005;226(11):1846-1850.
- Carter TD, Fuller BD, Shaver SL, Foy DS. Retrospective evaluation of the efficacy of fluconazole for the treatment of coccidioidomycosis in dogs: 49 cases (2015-2020). J Am Vet Med Assoc. 2022;260(10):1200-1205.
- Arbona N, Butkiewicz CD, Keyes M, Shubitz LF. Clinical features of cats diagnosed with coccidioidomycosis in Arizona, 2004-2018. J Feline Med Surg. 2020;22(2):129-137.
- Shubitz LF, Schlacks S, Vishkautsan P, et al. Posaconazole treatment of refractory coccidioidomycosis in dogs. J Vet Intern Med. 2021;35(6):2772-2777.
- Butkiewicz CD, Alcott CJ, Renschler J, et al. The utility of Coccidioides antigen and antibody detection in cerebrospinal fluid in the diagnosis of canine central nervous system coccidioidomycosis. Am J Vet Res. 2021;83(1):59-63.
- Jaffey JA, Hanzlicek AS, Rayhel LH, et al. A treatment monitoring protocol to determine clinical remission in dogs with pulmonary coccidioidomycosis. J Vet Intern Med. 2026;40(1).